BNET Industries

PDL BioPharma Inc.

(PDLI) is in the Pharma Industry

Market Cap:$945.4M
Last Fiscal Year Sales:$294.2M
  • Public
  • US
Dow Jones Description

PDL BioPharma, Inc. pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and autoimmune diseases.

Interim Chief Executive Officer
L. Patrick Gage
Number of Employees 6
Contact Information

1400 Seaport Boulevard

Redwood City, California 94063

www.pdl.com

650-454-1000

NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414

Recent Events

  • Data Pointing To Global Economic Recovery May Help Sentiment -RTTNews Daily Market Analysis

    11/13/09 - Stock Split / Dividend - View Story

  • PDL BioPharma Announces Special Dividend Payment Record Date of December 1 and Payment Date of...

    11/12/09 - Stock Split / Dividend - View Story

  • PDL BioPharma Announces Third Quarter 2009 Financial Results

    10/28/09 - Financial Announcement - View Story

  • PDL BioPharma Completes October 1 Special Dividend Payment

    10/04/09 - Stock Split / Dividend - View Story

  • PDL BioPharma, Inc. PDLI Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million

    9/08/09 - Financial Announcement - View Story

  • Merck vaccines chief steps down

    8/05/09 - Board Member - Entering - View Story

  • PDL BioPharma names Selick to board of directors

    8/03/09 - Board Member - Entering - View Story

News & Analysis

pdl biopharma inc. - All News and Analysis

Decision Makers

Name (plus bio) Position
L. Patrick Gage Interim Chief Executive Officer
Andrew L. Guggenhime Senior Vice President and Chief Financial Officer
Mark McCamish Senior Vice President and Chief Medical Officer
Richard Murray Executive Vice President and Chief Scientific Officer
Brett Schmidli Senior Vice President, Technology Operations
Douglas Ebersole Senior Vice President & Secretary
Jaisim Shah Senior Vice President, Marketing and Business Affairs
Behrooz Najafi Vice President, Information Technology
Cynthia Shumate Vice President, Intellectual Property
Debbie Law Vice President, Research
Eric Emery Vice President, Manufacturing
George T. Jue Vice President, Finance & Controller
Graeme Currie Vice President, Clinical Operations
Helen S. Kim Vice President, Marketing
Julie Badillo Vice President, Biopharmaceutical Program Management
Karen Wilson Vice President, Finance & Principal Accounting Officer
Laurie Torres Vice President, HR
Lyn D. Olson Vice President, Quality & Compliance
Maninder Hora Vice President, Process Development
Mark P. Backer Vice President, Technology Development
Robert Kirkman Vice President, Business Development & Corp Communications
Robert Stagg Vice President, Regulatory Affairs & Safety
William R. Benjamin Vice President, Res & Clinical Technology

Board of Directors

Name (plus bio) Position
Karen A. Dawes Chairman
Bradford S. Goodwin Board of Directors
Frederick Frank Board of Directors
Jody S. Lindell Board of Directors
Jon S. Saxe Board of Directors
Joseph Klein III Board of Directors
Laurence Jay Korn Board of Directors

Organization Position Status
PDL BioPharma, Inc. Interim Chief Executive Officer Current
Flagship Ventures Venture Partner Current
Adnexus Chairman of the Board Current
Acceleron Pharma Inc Board of Directors Current
Functional Genetics, Inc. Board of Directors Current
Alvine Pharmaceuticals, Inc. Director Current
Biotechnology Institute Board of Directors Current
The Philadelphia Orchestra Association Board of Directors Current
PDL BioPharma, Inc. Board of Directors Current
Warburg, Pincus, LLC Life Sciences Advisory Board Current
Genetics Institute, Inc. President Former
Wyeth Research President Former
Genetics Institute, Inc. Chief Operating Officer Former
Wyeth Research Chief Scientific Officer Former
Wyeth Research Senior Vice President, Science and Technology Former
Hoffmann-La Roche Inc. Vice President, Exploratory Research Former
Genetics Institute, Inc. R&D Head Former
Hoffmann-La Roche Inc. Research Management Former
Neose Technologies, Inc. Chairman Former
PDL BioPharma, Inc. Chairman Former
Wyeth Research Director Former
University of Chicago Ph.D. In Biophysics Former
University of Chicago Bachelors Degree In Physics Former
Massachusetts Institute of Technology B.S. in Physics Former
Acceleron Pharma Inc Chairman of the Board Current

Organization Position Status
PDL BioPharma, Inc. Senior Vice President and Chief Financial Officer Current
Neoforma Inc. CFO Former
Wells Fargo & Company Assistant Vice President Former
Northwestern University Master of Management degree Former
Middlebury College Bachelor of Arts degree in international politics and economics Former

Organization Position Status
PDL BioPharma, Inc. Senior Vice President and Chief Medical Officer Current

Organization Position Status
PDL BioPharma, Inc. Executive Vice President and Chief Scientific Officer Current
PDL BioPharma, Inc. Board of Directors Current

Organization Position Status
PDL BioPharma, Inc. Senior Vice President, Technology Operations Current

Organization Position Status
PDL BioPharma, Inc. Senior Vice President & Secretary Current

Organization Position Status
PDL BioPharma, Inc. Senior Vice President, Marketing and Business Affairs Current

Organization Position Status
PDL BioPharma, Inc. Vice President, Information Technology Current

Organization Position Status
PDL BioPharma, Inc. Vice President, Intellectual Property Current

Organization Position Status
PDL BioPharma, Inc. Vice President, Research Current

Organization Position Status
PDL BioPharma, Inc. Vice President, Manufacturing Current

Organization Position Status
PDL BioPharma, Inc. Vice President, Finance & Controller Current

Organization Position Status
PDL BioPharma, Inc. Vice President, Clinical Operations Current
Dayspring Pharma Board of Directors Current
ESP Pharma, Inc. Vice President Former
ESP Pharma, Inc. Senior Director Former
Gilead Sciences, Inc. Director of Clinical Research Former
Hepsera Former
Aston University Ph.D. Former

Organization Position Status
PDL BioPharma, Inc. Vice President, Marketing Current

Organization Position Status
PDL BioPharma, Inc. Vice President, Biopharmaceutical Program Management Current

Organization Position Status
PDL BioPharma, Inc. Vice President, Finance & Principal Accounting Officer Current
Monogram Biosciences, Inc. Chief Financial Officer Former
Novare Surgical Systems, Inc. Chief Financial Officer & Vice President, Operations Former
Deloitte & Touche LLP Senior Manager Former
University of California, Berkeley B.S., Business Former

Organization Position Status
PDL BioPharma, Inc. Vice President, HR Current

Organization Position Status
PDL BioPharma, Inc. Vice President, Quality & Compliance Current

Organization Position Status
PDL BioPharma, Inc. Vice President, Process Development Current

Organization Position Status
PDL BioPharma, Inc. Vice President, Technology Development Current

Organization Position Status
Cyclacel Pharmaceuticals, Inc. Vice President Current
PDL BioPharma, Inc. Vice President, Business Development & Corp Communications Current

Organization Position Status
PDL BioPharma, Inc. Vice President, Regulatory Affairs & Safety Current

Organization Position Status
PDL BioPharma, Inc. Vice President, Res & Clinical Technology Current

Organization Position Status
ESP Pharma, Inc. Current
PDL BioPharma, Inc. Chairman Current
Repligen Corporation Board of Directors Current
Depomed, Inc. Board of Directors Current
Genetics Institute, Inc. Vice President, Commercial Operations Former
Pfizer Inc. Vice President Former
Bayer Corporation Former
Harvard Business School MBA degree Former
Simmons College degrees in English Former

Bradford S. Goodwin joined us as a director in January 2007. Mr. Goodwin is currently President and CEO of Keren Pharmaceuticals, Inc. and director of Facet Biotech Corporation. His prior public company board services include PDL BioPharma and CoTherix, Inc. From 2001 to 2006, he was Chief Executive Officer and Director of Novacea, Inc., a publicly-held biopharmaceutical company focused on in-licensing, developing and commercializing novel therapies for cancer. Prior to Novacea, Mr. Goodwin was President, Chief Operating Officer and Founder of Collabra Pharma, a company focused on pharmaceutical product licensing and development. Before starting Collabra, he held various senior executive positions with Genentech, Inc., including Vice President of Finance. After becoming a CPA while working as an auditor at PricewaterhouseCoopers, he served on expert advisory committees of the American Institute of Certified Public Accountants, the Financial Accounting Standards Board and the International Accounting Standards Board. Mr. Goodwin holds a BS in business administration from the University of California, Berkeley.

Organization Position Status
Rigel Pharmaceuticals, Inc. Board of Directors Current
PDL BioPharma, Inc. Board of Directors Current

Organization Position Status
Yale School of Management Advisory Director Current
Landec Corporation Vice Chairman and Director of Lehman Brothers Current
Harvard School of Public Health Advisory Director Current
PureTech Ventures Senior Advisor Current
Salk Institute Director Current
Orbimed Advisors, LLC Chairman of The Board Current
Epix, Inc. Chairman of The Board Current
Predix Pharmaceuticals Holdings, Inc. Chairman of The Board Current
Business Engine, Inc. Director Current
Hemobiotech, Inc. Vice Chairman of Lehman Brothers Current
Egeen Intl. Corp. Vice Chairman Current
Kinemed, Inc Vice Chairman Current
EPIX Pharmaceuticals, Inc. Board of Directors Current
Institute for Systems Biology Director Current
Celtic Pharma Vice Chairman Current
Ophthalmopharma AG. Board of Directors Current
Pharmaceutical Product Development, Inc. Director Current
Diagnostic Products Corporation Director Current
1-800-Doctors, Inc. Director Current
EPIX Pharmaceuticals, Inc. Board of Directors Current
New York Society of Security Analysts Board of Directors Current
PDL BioPharma, Inc. Board of Directors Current
Peter J. Solomon Company Vice Chairman Current
Harvard School of Public Health Advisory Board Member Current
eSoft, Incorporated Director Current
New York Society of Security Analysts Member Current
Smith Barney Vice President Former
Lehman Brothers Holdings Inc. Senior Managing Director Former
Lehman Brothers Holdings Inc. partner Former
Swedish American Life Science Board of Directors Former
Lehman Brothers Holdings Inc. Director Former
Lehman Brothers Holdings Inc. Vice Chairman Former
Barclays Capital Vice Chairman Former
Landec Corporation Board of Directors Former
Stanford University MBA Former
Stanford Graduate School of Business MBA Former
Yale University B.A. Former

Organization Position Status
First Republic Bank Director Current
The Cooper Companies, Inc. Board of Directors Current
PDL BioPharma, Inc. Board of Directors Current
KPMG International partner Former
Stanford University M.B.A. Former
Stanford University B.A Former

Organization Position Status
Needham Capital Partners Limited Partner Current
Ptv Sciences Director of the Company Current
Hoffmann-La Roche Inc. Head of Patent Law Current
Ask About Patents Current
ESP Pharma, Inc. Current
Vistagen, Inc. Chairman Current
Entelos, Inc. Chairman of the Board Current
SciClone Pharmaceuticals, Inc. Chairman Current
Sciele Pharma, Inc. Audit Committee Chairman Current
InSite Vision Incorporated Director Current
Id Biomedical Corp Director Current
Incyte Genomics, Inc. Director Current
Questcor Pharmaceuticals, Inc. Director Current
DURECT Corporation Board of Directors Current
PDL BioPharma, Inc. Board of Directors Current
M Stage Pharmacueticals, Inc Board of Directors Current
Astex Therapeutics Limited Board of Directors Current
Barofold, Inc Board of Directors Current
Synergen, Inc. Chief Executive Officer Former
Synergen, Inc. President Former
PDL BioPharma, Inc. President Former
Roche Vice President, Licensing & Corporate Development Former
Hoffmann-La Roche Inc. Vice President of Licensing & Corporate Development Former
Iconix Pharmaceuticals, Inc. Limited Partner Former
Point Biomedical Corporation Limited Partner Former
Institutional Venture Partners Executive-In-Residence Former
PDL BioPharma, Inc. Director Former
Iconix Pharmaceuticals, Inc. Director Former
Incyte Corporation Director Former
Synergen, Inc. Director Former
The George Washington University J.D. Former
New York University School of Law Ll.M. Former
New York University L.L.M. Former
Carnegie Mellon University Bsche Former

Joseph Klein III was elected a director of the Company in July 2007. Mr. Klein currently serves as Managing Director of Gauss Capital Advisors, LLC, a financial consulting and investment advisory firm focused on biopharmaceuticals, which he founded in March 1998. Since September 2003, Mr. Klein has also served as a Venture Partner of Red Abbey Venture Partners, LP, a life sciences private equity fund. From September 2001 to September 2002, Mr. Klein was a Venture Partner of MPM Capital, a healthcare venture capital firm. Mr. Klein served as Vice President, Strategy, for Medical Manager Corporation, a leading developer of physician office management information systems, from June 1999 until it merged with WebMD Corporation in September 2000. In the 10 years prior to joining Medical Manager Corporation, Mr. Klein was a portfolio manager and securities analyst at T. Rowe Price Associates, Inc. and The Kaufmann Fund, Inc. Mr. Klein serves on the Board of Directors of BioMarin Pharmaceutical Inc., Isis Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc. and Savient Pharmaceuticals, Inc., each of which is a publicly traded company. Mr. Klein received a B.A. in economics from Yale University and an M.B.A. from the Stanford Graduate School of Business.

Organization Position Status
PDL BioPharma, Inc. Board of Directors Current

Organization Position Status
PDL BioPharma, Inc. Board of Directors Current

Executive News

  • Sinapis Pharma Announces Frederick Frank as Consultant

    PR Newswire - 9/08/09 - View Story

  • Swedish-American Life Science Summit (SALSS) to Address Major Issues Including Healthcare Reform, Synthetic Biology and Innovative Financing for Biotechs

    Pharma Live - 8/18/09 - View Story

advertisement
     PDLI $7.90 -0.11 (-1.37% )
Intraday | 3 Month | 6 Month | 1 Year
Average Volume 3,067,020
Shares Outstanding 119.67M
Market Cap 945.4M
Year High 9.92
Year Low 5.2
Earnings Per Share 1.83
P/E Ratio 4.32
Dividend 1.00
Yield 12.66
IndustryTop Rated
advertisement
Click Here